Tags

Type your tag names separated by a space and hit enter

[Treatment of Pompe's disease with recombinant enzymes].
Verh K Acad Geneeskd Belg 1998; 60(4):347-57VK

Abstract

Pompe disease is caused by the congenital deficiency of the lysosomal enzyme acid alpha-glucosidase. The accumulation of lysosomal glycogen results in a fatal myopathy and cardiomyopathy. We developed an enzyme replacement therapy based on recombinant human acid alpha-glucosidase enzyme targeted to the organs of interest by the presence of mannose-6-phosphate on this precursor enzyme and a manose-6-phosphate receptor present in muscle and heart. Using molecular techniques and following extensive selection, Chinese hamster ovary cells were developed that produced very large quantities of precursor human acid alpha-glucosidase in the culture medium. An improved method of purification of this precursor enzyme from tissue culture medium was developed. This purified precursor enzyme was taken up efficiently by patient's fibroblasts, and corrected with a single dose the lysosomal glycogen accumulation for one week. Finally, intravenous administration of the recombinant enzyme corrected the pathology and symptoms of an animal model of this disorder, the acid alpha-glucosidase deficient Japanese quail.

Authors+Show Affiliations

U.Z. Gasthuisberg, Afdeling Kindergeneeskunde, Leuven.

Pub Type(s)

English Abstract
Journal Article

Language

dut

PubMed ID

9883081

Citation

Van Hove, J L.. "[Treatment of Pompe's Disease With Recombinant Enzymes]." Verhandelingen - Koninklijke Academie Voor Geneeskunde Van Belgie, vol. 60, no. 4, 1998, pp. 347-57.
Van Hove JL. [Treatment of Pompe's disease with recombinant enzymes]. Verh K Acad Geneeskd Belg. 1998;60(4):347-57.
Van Hove, J. L. (1998). [Treatment of Pompe's disease with recombinant enzymes]. Verhandelingen - Koninklijke Academie Voor Geneeskunde Van Belgie, 60(4), pp. 347-57.
Van Hove JL. [Treatment of Pompe's Disease With Recombinant Enzymes]. Verh K Acad Geneeskd Belg. 1998;60(4):347-57. PubMed PMID: 9883081.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of Pompe's disease with recombinant enzymes]. A1 - Van Hove,J L, PY - 1999/1/12/pubmed PY - 1999/1/12/medline PY - 1999/1/12/entrez SP - 347 EP - 57 JF - Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie JO - Verh. K. Acad. Geneeskd. Belg. VL - 60 IS - 4 N2 - Pompe disease is caused by the congenital deficiency of the lysosomal enzyme acid alpha-glucosidase. The accumulation of lysosomal glycogen results in a fatal myopathy and cardiomyopathy. We developed an enzyme replacement therapy based on recombinant human acid alpha-glucosidase enzyme targeted to the organs of interest by the presence of mannose-6-phosphate on this precursor enzyme and a manose-6-phosphate receptor present in muscle and heart. Using molecular techniques and following extensive selection, Chinese hamster ovary cells were developed that produced very large quantities of precursor human acid alpha-glucosidase in the culture medium. An improved method of purification of this precursor enzyme from tissue culture medium was developed. This purified precursor enzyme was taken up efficiently by patient's fibroblasts, and corrected with a single dose the lysosomal glycogen accumulation for one week. Finally, intravenous administration of the recombinant enzyme corrected the pathology and symptoms of an animal model of this disorder, the acid alpha-glucosidase deficient Japanese quail. SN - 0302-6469 UR - https://www.unboundmedicine.com/medline/citation/9883081/[Treatment_of_Pompe's_disease_with_recombinant_enzymes]_ DB - PRIME DP - Unbound Medicine ER -